cassava
sciences
announces
additional
clinical
data
phase
study
sumifilam
alzheimer
disease
alzheimer
patients
treated
sumifilam
showed
statistically
significant
p
treatment
benefit
protein
triggers
neuroinflammation
loss
neurons
alzheimer
patients
treated
sumifilam
also
showed
treatment
benefit
p
barrier
integrity
clinical
dataset
presented
november
ctad
conference
austin
texas
globe
newswire
cassava
sciences
nasdaq
sava
today
announced
additional
clinical
data
phase
study
sumifilam
lead
drug
candidate
patients
alzheimer
disease
clinical
study
funded
national
institutes
health
nih
sumifilam
decreased
levels
protein
called
improved
measurements
integrity
barrier
bbb
ability
drug
candidate
decrease
improve
bbb
integrity
patients
alzheimer
disease
previously
reported
science
literature
sumifilam
proprietary
small
molecule
oral
drug
restores
normal
shape
function
altered
filamin
protein
brain
ability
improve
multiple
biomarkers
disease
one
drug
unique
achievement
said
remi
barbier
president
ceo
cassava
sciences
believe
exciting
clinical
results
create
time
rapid
strategic
momentum
company
include
development
plans
evaluate
sumifilam
phase
clinical
program
patients
alzheimer
additional
phase
study
results
additional
clinical
data
include
changes
levels
protein
measurements
integrity
barrier
baseline
day
versus
placebo
sumifilam
significantly
reduced
levels
cerebrospinal
fluid
csf
decreased
p
patients
treated
mg
sumifilam
decreased
p
patients
treated
mg
sumifilam
sumifilam
significantly
improved
integrity
barrier
bbb
csf
igg
decreased
p
patients
treated
mg
sumifilam
csf
igg
decreased
p
patients
treated
mg
sumifilam
csf
albumin
decreased
p
patients
treated
mg
sumifilam
csf
albumin
decreased
p
patients
treated
mg
sumifilam
sumifilam
improved
albumin
ratio
test
barrier
bbb
permeability
bbb
permeability
clinically
evaluated
comparing
levels
albumin
csf
plasma
albumin
ratio
test
bbb
permeability
albumin
protein
synthesized
csf
hence
albumin
csf
necessarily
comes
plasma
bbb
albumin
ratio
frequently
elevated
patients
dementia
various
disorders
phase
study
albumin
ratio
unchanged
alzheimer
patients
placebo
albumin
ratio
improved
approximately
points
patients
treated
sumifilam
mg
mg
respectively
days
changes
albumin
ratio
treatment
group
treatment
day
day
placebo
change
mg
sumifilam
mg
sumifilam
endogenous
potent
protein
sometimes
called
danger
elevated
patients
alzheimer
disease
neurodegenerative
disorders
many
disorders
elevated
levels
induce
neuroinflammation
tissue
damage
eventually
cell
death
preclinical
research
shown
inhibiting
improves
outcomes
neurodegenerative
disease
models
decreasing
neuroinflammation
improving
learning
memory
reports
nearly
scientific
publications
research
past
decade
highlighting
molecule
potential
importance
clinical
research
barrier
bbb
bbb
complex
border
cells
along
blood
vessels
prevent
unwanted
substances
blood
entering
brain
bbb
integrity
essential
brain
health
healthy
bbb
system
selectively
allows
passage
molecules
brain
water
glucose
blocking
passage
molecules
may
damage
brain
levels
igg
antibodies
albumin
protein
cerebrospinal
fluid
csf
index
bbb
integrity
elevated
levels
evidence
leaky
impaired
bbb
albumin
protein
found
high
levels
plasma
low
levels
csf
normally
cross
bbb
presentation
ctad
clinical
results
phase
study
sumifilam
selected
oral
presentation
international
conference
clinical
trials
alzheimer
disease
ctad
ctad
prestigious
annual
conference
focused
alzheimer
clinical
research
takes
place
year
virtual
event
november
saturday
november
company
scientists
present
oral
presentation
titled
sumifilam
significantly
improves
eleven
csf
biomarkers
randomized
clinical
trial
alzheimer
disease
company
ctad
presentation
available
website
https
phase
study
design
phase
randomized
clinical
study
sumifilam
formerly
patients
alzheimer
disease
age
randomized
mg
mg
oral
sumifilam
matching
placebo
treatment
administered
twice
daily
days
nine
study
sites
enrolled
patients
clinical
diagnosis
alzheimer
disease
confirmed
state
examination
mmse
csf
aÎ²
ratio
safety
assessed
ecgs
clinical
labs
adverse
event
monitoring
physical
examinations
previously
announced
clinical
phase
data
previously
announced
september
sumifilam
safe
patient
discontinuations
alzheimer
patients
treated
mg
mg
sumifilam
days
showed
statistically
significant
p
improvements
eight
biomarkers
disease
pathology
neurodegeneration
neuroinflammation
versus
alzheimer
patients
took
placebo
addition
alzheimer
patients
treated
sumifilam
showed
improvements
validated
tests
episodic
memory
spatial
working
memory
versus
patients
took
placebo
effect
sizes
cognitive
improvements
correlated
strongly
decreases
biomarker
leads
tangles
brain
sumifilam
decreased
brain
levels
versus
placebo
study
achieved
response
rate
defined
proportion
study
participants
taking
sumifilam
showed
improvements
biomarkers
study
march
announced
initiation
study
evaluate
sumifilam
patients
alzheimer
disease
extension
study
monitor
safety
tolerability
sumifilam
mg
months
study
target
enrollment
approximately
patients
alzheimer
disease
study
exceeded
enrollment
study
employs
alzheimer
disease
assessment
subscale
assess
cognitive
symptoms
dementia
neuropsychiatric
index
npi
assess
behavioral
symptoms
cassava
sciences
plans
announce
results
interim
analysis
additional
safety
cognition
data
collected
patients
enrolled
study
alzheimer
disease
alzheimer
disease
progressive
brain
disorder
destroys
memory
thinking
skills
currently
drug
therapies
halt
alzheimer
disease
much
less
reverse
course
alone
approximately
million
people
currently
living
alzheimer
disease
approximately
people
age
older
developed
alzheimer
number
people
living
alzheimer
disease
expected
grow
dramatically
years
ahead
resulting
growing
social
economic
sumifilam
sumifilam
proprietary
small
molecule
oral
drug
restores
normal
shape
function
altered
filamin
flna
scaffolding
protein
brain
altered
flna
brain
disrupts
normal
function
neurons
leading
alzheimer
pathology
neurodegeneration
neuroinflammation
underlying
science
sumifilam
published
journals
including
journal
neuroscience
neurobiology
aging
journal
biological
chemistry
neuroimmunology
neuroinflammation
journal
prevention
alzheimer
disease
company
also
developing
investigational
diagnostic
called
savadx
detect
alzheimer
disease
simple
blood
test
sumifilam
savadx
developed
product
candidates
substantially
funded
research
grant
awards
national
institutes
health
nih
cassava
sciences
owns
worldwide
development
commercial
rights
research
programs
alzheimer
disease
related
technologies
without
royalty
obligations
third
party
patent
protection
area
runs
plus
extensions
includes
seven
issued
patents
related
patent
filings
applications
cassava
sciences
cassava
sciences
mission
discover
develop
innovations
chronic
neurodegenerative
conditions
past
years
cassava
sciences
combined
technology
new
insights
neurobiology
develop
novel
solutions
alzheimer
disease
information
please
visit
https
information
contact
eric
schoen
chief
financial
officer
cassava
sciences
eschoen
cassava
sciences
phase
study
sumifilam
alzheimer
disease
funded
clinical
research
grant
national
institutes
health
nih
nia
content
press
release
solely
responsibility
cassava
sciences
necessarily
represent
official
views
nih
nia
cautionary
note
regarding
statements
press
release
contains
statements
purposes
private
securities
litigation
reform
act
act
cassava
sciences
claims
protection
safe
harbor
statements
contained
act
statements
statements
historical
fact
contained
press
release
including
limited
statements
regarding
status
current
future
clinical
studies
sumifilam
including
intention
conduct
phase
clinical
program
interpretation
results
phase
clinical
studies
including
cognition
data
plans
announce
results
interim
analysis
ongoing
study
potential
health
benefits
changes
levels
biomarkers
verbal
commentaries
made
cassava
sciences
employees
potential
benefits
company
product
candidates
alzheimer
disease
statements
statements
based
largely
company
current
expectations
projections
future
events
statements
speak
date
press
release
subject
number
risks
uncertainties
assumptions
including
limited
risks
relating
ability
conduct
complete
clinical
studies
expected
timelines
demonstrate
specificity
safety
efficacy
potential
health
benefits
product
candidates
severity
duration
health
care
precautions
given
pandemic
unanticipated
impacts
pandemic
business
operations
including
described
section
entitled
risk
factors
cassava
sciences
annual
report
form
year
ended
december
future
reports
filed
sec
light
risks
uncertainties
assumptions
statements
events
discussed
press
release
inherently
uncertain
may
occur
actual
results
could
differ
materially
adversely
anticipated
implied
statements
accordingly
rely
upon
statements
predictions
future
events
except
required
law
company
disclaims
intention
responsibility
updating
revising
statements
contained
press
release
information
regarding
risks
related
business
investors
consult
filings
sec
available
sec
website
source
alzheimer
association
alzheimer
disease
facts
figures
available
online
https
media
documents
